Group One Trading
OVID icon

Group One Trading’s Ovid Therapeutics OVID Stock Holding History

Group One Trading’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$56.2K Buy
22,580
+3,917
+21% +$10.2K ﹤0.01% 5151
2026
Q2 		$50.2K Buy
18,663
+5,417
+41% +$14K ﹤0.01% 5400
2026
Q1 		$29.4K Buy
+13,246
New +$23.7K ﹤0.01% 5685
2025
Q4 		– Sell
-188,295
Closed -$290K – 8885
2025
Q3 		$245K Buy
+188,295
New +$163K ﹤0.01% 4457
2022
Q4 		– Sell
-1,532
Closed -$3K – 7872
2022
Q3 		$3K Sell
1,532
-36
-2% -$75 ﹤0.01% 7038
2022
Q2 		$3K Sell
1,568
-1,500
-49% -$3.62K ﹤0.01% 7318
2022
Q1 		$10K Sell
3,068
-9,838
-76% -$30.9K ﹤0.01% 7162
2021
Q4 		$41K Sell
12,906
-41,401
-76% -$142K ﹤0.01% 6478
2021
Q3 		$182K Sell
54,307
-11,394
-17% -$41.5K ﹤0.01% 5271
2021
Q2 		$257K Sell
65,701
-100,655
-61% -$397K ﹤0.01% 4956
2021
Q1 		$669K Buy
166,356
+100,721
+153% +$335K ﹤0.01% 3702
2020
Q4 		$152K Buy
65,635
+65,573
+105,763% +$306K ﹤0.01% 4268
2020
Q3 		$0 Sell
62
-8,338
-99% -$55.8K ﹤0.01% 6425
2020
Q2 		$62K Buy
+8,400
New +$39.3K ﹤0.01% 4225

Other funds holding OVID

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

Group One Trading's OVID Position: Q3 2026 in Review

Group One Trading increased its Ovid Therapeutics (OVID) stake by 21% in Q3 2026, buying an estimated $10.2K and bringing the position to 22,580 shares worth $56.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5151.

Group One Trading first reported a position in OVID in Q2 2020 and has held it in 14 quarters since. The position peaked at $669K in Q1 2021. 47 funds tracked by Wall St. Rank hold OVID as of Q3 2026.

  • Group One Trading held 22,580 shares of Ovid Therapeutics worth $56.2K as of Q3 2026.
  • Group One Trading bought 3,917 Ovid Therapeutics shares in Q3 2026, an estimated $10.2K.
  • Ovid Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q3 2026, its #5151 holding.
  • Group One Trading first reported a position in Ovid Therapeutics in Q2 2020 and has held it in 14 quarters since.
  • Group One Trading's Ovid Therapeutics position peaked at $669K in Q1 2021.
  • 47 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2026.

Based on Group One Trading's 13F filing for Q3 2026, filed 10 Nov 2026.